Beam Therapeutics Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Beam Therapeutics filed its Q1 2024 10-Q, detailing financial positions and fair value measurements.</b>

AI Summary

Beam Therapeutics Inc. (BEAM) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Beam Therapeutics reported financial results for the quarter ended March 31, 2024. The company's filing includes details on fair value measurements for various assets and liabilities. Research and development expenses for the period January 1, 2023, to March 31, 2023, are noted. The filing references contingent consideration liabilities related to product and technology agreements. Information on common stock and additional paid-in capital is provided as of March 31, 2024.

Why It Matters

For investors and stakeholders tracking Beam Therapeutics Inc., this filing contains several important signals. Investors can assess the company's financial health and valuation of its assets and liabilities. The filing provides insights into the company's ongoing R&D activities and potential future obligations.

Risk Assessment

Risk Level: medium — Beam Therapeutics Inc. shows moderate risk based on this filing. The company operates in the highly regulated and competitive biotechnology sector, with significant R&D expenses and potential future liabilities related to its product candidates.

Analyst Insight

Monitor Beam Therapeutics' progress in clinical trials and its ability to manage contingent liabilities as it advances its gene editing therapies.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q Filing)
• 2023-01-01 to 2023-03-31 — R&D Expense Period (10-Q Filing)
• 2023-12-31 — Previous Year End Date (Fair Value Measurements)
• 2024-03-31 — Current Quarter End Date (Fair Value Measurements)

Key Players & Entities

• Beam Therapeutics Inc. (company) — Filer
• Verve Therapeutics Inc (company) — Mentioned in relation to common stock
• Harvard License Agreement (company) — Related to fair value measurements
• Jefferies Llc Sales Agreement (company) — Related to At The Market sales
• Guide Therapeutics Incorporated (company) — Mentioned in relation to Merger Agreement

FAQ

Risk Factors

• Fair Value Measurements [medium — financial]: The company utilizes Level 3 inputs for fair value measurements of certain assets and liabilities, which involve significant judgment and estimation.
• Contingent Consideration [medium — financial]: Contingent consideration liabilities related to product and technology agreements introduce uncertainty and potential future financial obligations.
• Biotechnology Industry Risks [high — regulatory]: The company operates in a highly regulated industry with inherent risks associated with drug development, clinical trials, and regulatory approvals.

Key Dates

• 2024-03-31: Quarterly Report (10-Q) Filing — Reporting period end for the financial statements.

Glossary

Contingent Consideration

An amount that is conditional on the occurrence of a future event. (Represents potential future financial obligations that can impact the company's financial position.)

Fair Value Measurements

The price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. (Crucial for valuing assets and liabilities, especially in the absence of active markets.)

Level 3 Inputs

Unobservable inputs that are used to measure fair value, reflecting the reporting entity's own assumptions. (Indicates a higher degree of estimation and subjectivity in valuation.)

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select

Filing Documents

• beam-20240331.htm (10-Q) — 1698KB
• beam-ex10_1.htm (EX-10.1) — 19KB
• beam-ex10_2.htm (EX-10.2) — 15KB
• beam-ex31_1.htm (EX-31.1) — 16KB
• beam-ex31_2.htm (EX-31.2) — 16KB
• beam-ex32_1.htm (EX-32.1) — 9KB
• beam-ex32_2.htm (EX-32.2) — 9KB
• img138500502_0.jpg (GRAPHIC) — 235KB
• 0000950170-24-053939.txt (&nbsp;) — 8551KB
• beam-20240331.xsd (EX-101.SCH) — 1296KB
• beam-20240331_htm.xml (XML) — 1584KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Other Comprehensive Loss 2 Condensed Consolidated Statements of Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 33 PART II Other Information 34 Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 6. Exhibits 35

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Financial St atements (Unaudited)

Item 1. Financial St atements (Unaudited) Beam Therapeutics Inc. Condensed Consolidated Ba lance Sheets ( Unaudited ) (in thousands, except share and per share amounts) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 287,848 $ 435,895 Marketable securities 806,706 753,981 Prepaid expenses and other current assets 27,156 21,167 Total current assets 1,121,710 1,211,043 Property and equipment, net 120,922 124,960 Restricted cash 6,452 8,719 Operating lease right-of-use assets 109,023 112,846 Other assets 1,689 2,146 Total assets $ 1,359,796 $ 1,459,714 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,790 $ 1,617 Accrued expenses and other current liabilities 86,437 111,664 Derivative liabilities 13,700 10,800 Current portion of deferred revenue 72,111 68,706 Current portion of lease liability 12,181 12,778 Total current liabilities 187,219 205,565 Long-term lease liability 155,939 159,911 Contingent consideration liabilities 2,856 2,723 Long-term portion of deferred revenue 99,573 109,888 Other liabilities 719 298 Total liabilities 446,306 478,385 Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements ) Stockholders' equity: Preferred stock, $ 0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2024 and December 31, 2023, respectively — — Common stock, $ 0.01 par value; 250,000,000 shares authorized, 82,280,827 and 81,632,496 issued and outstanding at March 31, 2024 and December 31, 2023, respectively 823 816 Additional paid-in capital 2,202,146 2,169,798 Accumulated other comprehensive (loss) income ( 921 ) 604 Accumulated deficit ( 1,288,558 ) ( 1,189,889 ) Total stockholders' equity 913,490 981,329 Total lia